Compare Ascendis Pharma A/S (ASND) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Tripadvisor Inc Common Stock — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Tripadvisor Inc Common Stock trades at $13.89 (market cap $1.63B). The key difference: Ascendis Pharma A/S is far larger — about 10.9× Tripadvisor Inc Common Stock's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| ASND | TRIP | |
|---|---|---|
Market Cap | $17.74B | $1.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $19.14 |
52-Week Low | $163.32 | $9.24 |
Enterprise Value | $18.11B | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TRIP trades at $13.98, up 4.88% today, near the consensus price target of $13.87. The stock shows a bullish technical signal with support at $13 and resistance at $14. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026. The company's $700 million sale of TheFork to American Express in June 2026 provides a cash infusion but highlights strategic refocusing amid competitive pressures.
The outlook is cautious; while the sale simplifies the business and boosts liquidity, core revenue growth remains modest and net margins are thin at 0.99%. Analyst sentiment is neutral with 60.72% hold ratings. Key risks include execution on the narrowed strategy and travel industry volatility. The stock appears fairly valued with a P/E of 127.09 reflecting low earnings, but the P/S of 0.93 suggests potential if top-line expansion accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
